Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)

被引：0
|
作者：
Takahiro Niimura
Koji Miyata
Hirofumi Hamano
Yuuki Nounin
Hiroto Unten
Masaki Yoshino
Satoru Mitsuboshi
Fuka Aizawa
Kenta Yagi
Toshihiro Koyama
Mitsuhiro Goda
Yasunari Kanda
Yuki Izawa-Ishizawa
Yoshito Zamami
Keisuke Ishizawa
机构：
[1] Tokushima University Graduate School of Biomedical Sciences,Department of Clinical Pharmacology and Therapeutics
[2] Tokushima University Hospital,Clinical Research Center for Developmental Therapeutics
[3] Okayama University Hospital,Department of Pharmacy
[4] Niigata Prefectural Cancer Center Hospital,Department of Pharmacy
[5] Kaetsu Hospital,Department of Pharmacy
[6] Tokushima University Hospital,Department of Pharmacy
[7] Okayama University,Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
[8] National Institute of Health Sciences,Division of Pharmacology
[9] Taoka Hospital,Department of General Medicine
来源：
Drug Safety | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：545 / 552
页数：7
相关论文
共 50 条
  • [1] Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)
    Niimura, Takahiro
    Miyata, Koji
    Hamano, Hirofumi
    Nounin, Yuuki
    Unten, Hiroto
    Yoshino, Masaki
    Mitsuboshi, Satoru
    Aizawa, Fuka
    Yagi, Kenta
    Koyama, Toshihiro
    Goda, Mitsuhiro
    Kanda, Yasunari
    Izawa-Ishizawa, Yuki
    Zamami, Yoshito
    Ishizawa, Keisuke
    DRUG SAFETY, 2023, 46 (06) : 545 - 552
  • [2] Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database
    Huang, Sifu
    Bai, Xuefeng
    Fang, Taiyong
    Guo, Yanta
    Zheng, Kainan
    Lin, Xiahong
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2021, 22 (02): : 156 - 164
  • [3] Anaplastic lymphoma kinase inhibitors: risk of cardiovascular toxicities
    Reactions Weekly, 2023, 1956 (1) : 8 - 8
  • [4] Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database
    Mota, Diogo
    Rama, Tiago Azenha
    Severo, Milton
    Moreira, Andre
    ALLERGY, 2021, 76 (10) : 3209 - 3211
  • [5] Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database
    Gras-Champel, Valerie
    Batteux, Benjamin
    Masmoudi, Kamel
    Liabeuf, Sophie
    MUSCLE & NERVE, 2019, 60 (04) : 382 - 386
  • [6] Lupus Associated to TNF-Alpha Inhibitor in Children and Adults: A Disproportionality Analysis in the WHO Pharmacovigilance Database (Vigibase)
    Bouton, Justine
    Moulis, Florence
    Moulis, Guillaume
    Sommet, Agnes
    Rousseau, Vanessa
    Montastruc, Jean-Louis
    Durrieu, Genevieve
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 392 - 392
  • [7] The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis
    Thakre, Anuj
    Babbili, Akhilesh
    Thotamgari, Sahith Reddy
    Grewal, Udhayvir
    Beedupalli, Kavitha
    Dominic, Paari
    CIRCULATION, 2022, 146
  • [8] Acute kidney injury associated with febuxostat and allopurinol: An analysis of disproportionality based on the global pharmacovigilance database, VigiBase®
    Rey, A.
    Batteux, B.
    Masmoudi, K.
    Gras, V.
    Liabeuf, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 110 - 111
  • [9] Proton pump inhibitors induced lupus erythematosus: A disproportionality study using the French pharmacovigilance Database and VigiBase®
    Bataille, P.
    Lebrun-Vignes, B.
    Tubach, F.
    Senet, P.
    Aroux, M.
    Philibert, C.
    Soria, A.
    Chasset, F.
    Barbaud, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 106 - 106
  • [10] Baclofen and sleep apnoea syndrome: analysis of VigiBase® the WHO pharmacovigilance database
    Revol, B.
    Jullian-Desayes, I.
    Bailly, S.
    Mallaret, M.
    Tamisier, R.
    Agier, M. S.
    Lador, F.
    Joyeux-Faure, M.
    Pepin, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 42 - 42
12345